This study is to assess the mass balance of oral ABBV-1354 in healthy adult male participants.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Adverse Events (AEs)
Timeframe: Up to approximately 32 days
Number of Participants with Abnormal Change from Baseline in Vital Sign Measurements
Timeframe: Up to approximately 15 days
Change From Baseline in Electrocardiograms (ECGs)
Timeframe: Up to approximately 15 days
Number of Participants with Abnormal Change in Physical Examinations
Timeframe: Up to approximately 15 days
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
Timeframe: Up to approximately 15 days
Maximum observed concentration (Cmax) of ABBV-1354
Timeframe: Up to approximately 15 days
Time to Cmax (peak time, Tmax) of ABBV-1354
Timeframe: Up to approximately 15 days
Terminal phase elimination half-life (t1/2) of ABBV-1354
Timeframe: Up to approximately 15 days
Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration (AUCt) of ABBV-1354
Timeframe: Up to approximately 15 days
Area under the plasma concentration-time curve (AUC) from time 0 to infinite time (AUCinf) of ABBV-1354
Timeframe: Up to approximately 15 days
Amount of ABBV-1354 excreted in the urine over the sampling period (Aeu)
Timeframe: Up to approximately 15 days
Percent of ABBV-1354 excreted in the urine
Timeframe: Up to approximately 15 days
Amount of ABBV-1354 excreted in the feces over the sampling period (Aeu)
Timeframe: Up to approximately 15 days
Percent of ABBV-1354 radioactivity excreted in the feces
Timeframe: Up to approximately 15 days